First-line immune checkpoint inhibitors in older adults (≥75 years) with advanced esophageal squamous cell carcinoma: efficacy and safety

In this real-world cohort, first-line immunotherapy demonstrated promising efficacy and a manageable safety profile in patients aged ≥75 years with advanced esophageal squamous cell carcinoma. These findings provide valuable preliminary evidence supporting the use of immune checkpoint inhibitors in this understudied population and highlight the need for prospective validation to optimize therapeutic strategies.